Skip to main content
logo
Becton, Dickinson and Company (BDX)
NYSE: BDX · Real-Time Price · USD
195.49
+4.53 (2.37%)
At close: Nov 25, 2025, 4:00 PM EST
195.48
-0.01 (-0.01%)
After-hours: Nov 25, 2025, 7:44 PM EST

Revenue Breakdown

Millions USD. Fiscal year is Oct - Sep.
Fiscal Year
FY 2025FY 2024FY 2023FY 20222011 - 2021
Period Ending
Sep '25 Sep '24 Sep '23 Sep '22 2011 - 2021
Medication Delivery Solutions Revenue
4.58B
Log In
Log In
Log In
Upgrade
Medication Management Solutions Revenue
3.47B
Log In
Log In
Log In
Upgrade
Pharmaceutical Systems Revenue
2.32B
Log In
Log In
Log In
Upgrade
Advanced Patient Monitoring Revenue
1.08B
Log In
Log In
Log In
Upgrade
Specimen Management Revenue
1.87B
Log In
Log In
Log In
Upgrade
Diagnostic Solusions Revenue
1.84B
Log In
Log In
Log In
Upgrade
Integrated Diagnostic Solutions Revenue
3.71B
Log In
Log In
Log In
Upgrade
Biosciences Revenue
1.46B
Log In
Log In
Log In
Upgrade
Surgery Revenue
1.57B
Log In
Log In
Log In
Upgrade
Peripheral Intervention Revenue
2.00B
Log In
Log In
Log In
Upgrade
Urology and Critical Care Revenue
1.65B
Log In
Log In
Log In
Upgrade
Revenue (Other)
-3.71B
Log In
Log In
Log In
Upgrade
Revenue (Total)
21.84B
Log In
Log In
Log In
Upgrade

Revenue Breakdown 2

Millions USD. Fiscal year is Oct - Sep.
Fiscal Year
FY 2025FY 2024FY 2023FY 20222011 - 2021
Period Ending
Sep '25 Sep '24 Sep '23 Sep '22 2011 - 2021
Medical Revenue
11.46B
Log In
Log In
Log In
Upgrade
Life Sciences Revenue
5.17B
Log In
Log In
Log In
Upgrade
Interventional Revenue
5.22B
Log In
Log In
Log In
Upgrade
Revenue (Total)
21.84B
Log In
Log In
Log In
Upgrade

EBIT

Millions USD. Fiscal year is Oct - Sep.
Fiscal Year
FY 2025FY 2024FY 2023FY 20222011 - 2021
Period Ending
Sep '25 Sep '24 Sep '23 Sep '22 2011 - 2021
Medical Operating Income
-
Log In
Log In
Log In
Upgrade
Life Sciences Operating Income
-
Log In
Log In
Log In
Upgrade
Interventional Operating Income
-
Log In
Log In
Log In
Upgrade
Operating Income (Total)
2.58B
Log In
Log In
Log In
Upgrade
Updated Nov 6, 2025. Data Source: Fiscal.ai.